<DOC>
	<DOCNO>NCT00978198</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ASP1517 single multiple oral administration healthy non-elderly adult male subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study ASP1517 Healthy Non-elderly Male Volunteers</brief_title>
	<detailed_description>The study consist two part , single multiple dose . Within part participant randomize either ASP1517 placebo .</detailed_description>
	<criteria>Body weight : ≥50.0 kg , &lt; 80.0 kg BMI : ≥18.5 kg/m2 , &lt; 25.0 kg/m2 Eligible , judge investigator/subinvestigator base result physical examination ( subjective symptom objective finding ) test obtain screen time immediately study medication Supine blood pressure : Systolic blood pressure ≥90 mmHg , ≤130 mmHg ; Diastolic blood pressure ≤85 mmHg Pulse rate rest supine position : ≥40 bpm , &lt; 100 bpm Received investigational drug clinical postmarketing study within 120 day screen assessment Donated 400 mL whole blood within 90 day , 200 mL whole blood within 30 day , blood component within 14 day screen assessment Received medication within 7 day hospital admission schedule receive medication History drug allergy Upper gastrointestinal disease ( e.g . nausea , vomit , stomachache ) within 7 day study Excessive smoke drinking habit ( measure `` excessive '' : alcohol : 45 g/day , smoking : 20 cigarettes/day )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Plasma concentration</keyword>
	<keyword>ASP1517</keyword>
	<keyword>FG-4592</keyword>
</DOC>